Fig. 4From: Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinicsExpected benefit of recommended LDL-c reduction. Panel a and b shows the absolute risk reduction achievable with treatments aimed to reach LDL-c targets in each group stratified by starting LDL-c levels (number in brackets are the proportion of subjects each group over the entire population). Panel c Expected number of subjects experiencing CVD events over 10 years (/100,000 subjects) in case of unchanged or changed cholesterol-lowering treatmentsBack to article page